PRCT
PROCEPT BioRobotics Corp
$20.89
+1.14 (+5.77%)
At close · Jul 10
Market Cap
$1.19B
Shares
56,918,844
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$20.89
Open$20.13
Day$19.63–21.00
52W$19.35–62.17
Avg vol 30d1.5M
Short int7.7M · 13.4% float · 3.9d
Short vol56%
Last earningsApr 29, 2026
DataSep 2021–Jul 2026
Filing10-Q · Apr 30
Up next
Next earnings call
Aug 4, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−16%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−32%
trailing
YTD return
−34%
this year
Relative strength
−41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $29 — 200d above 50d
Institutional flow
Accumulating
9 of 257 funds reported for Jun 30 · net +10.0K sh shares · +1 new
Insider flow
Distributing
Net -$28.5K over 90 days · 100% sells
Short interest
Rising
13.45% of float · ▲ +0.6% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
257 holders — mid 3-yr range
Squeeze score
68
elevated · 0–100
Fundamentals
Revenue growth
+37%
Y/Y
Gross margin
64%
expanding
EPS growth
+2%
Y/Y
Free cash flow
$-58.3M
Balance sheet
$234.9M
net cash
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Apr 29, 2026
Revenue
· full year 2026
Initiated
$390M – $410M
prior FY $308.05M
midpoint +29.8% Y/Y
U.S. procedure growth
· full year 2026
Initiated
39% – 48%
Gross margin
· full year 2026
Initiated
65%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $25 › 200d $29 — 200d above 50d
Institutional flow
Accumulating
9 of 257 funds reported for Jun 30 · net +10.0K sh shares · +1 new
Insider flow
Distributing
Net -$28.5K over 90 days · 100% sells
Short interest
Rising
13.45% of float · ▲ +0.6% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
257 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $19
Now $21 · 4%
52-wk high $62
vs 200-day avg -28%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Handpiece average selling price | $3,500 | first quarter of 2026 | — |
|
|
|||
| U.S. average selling prices (new Hydros systems) | $485,000 | first quarter of 2026 | — |
| U.S. handpieces sold as percent of U.S. procedures | 95% | first quarter of 2026 | — |
| U.S. Hydros systems sold | 49 | first quarter of 2026 | — |
| U.S. install base | 765 | March 31, 2026 | +6.5% |
|
|
|||
| U.S. procedures | 12,200 | first quarter of 2026 | — |
|
|
|||
| adjusted EBITDA loss non-GAAP | -$18.1M | Q1 2026 call | — |
| handpieces sold as percentage of procedures | 95% | Q1 2026 call | — |
| Hydros systems sold (U.S.) | 49 | Q1 2026 call | — |
| U.S. handpiece average selling price | $3,500 | Q1 2026 call | — |
| U.S. Hydros system average selling price | $485,000 | Q1 2026 call | — |
| U.S. installed base | 765 | Q1 2026 call | — |
| U.S. procedures completed | 12,200 | Q1 2026 call | — |
| New systems sold | 65 | Q4 2025 | — |
| U.S. handpieces sold | 9,400 | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRCT
this stock
PROCEPT BioRobotics Corp
|
$1.19B | -33.6% | +37.2% | — | 13.4% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRCT | -0.7% | -28.2% | -31.5% | -7.5% | -33.6% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.0% | -32.3% | -40.6% | -8.6% | -44.3% |